discontinu coverag
effect immedi discontinu coverag
assertio due realloc resourc market cap
current prior research assertio
longer reli upon
final rate equal-weight discontinu coverag assertio due
realloc team resourc equal-weight rate reflect balanc
posit neg posit includ rel low valuat
ebitda toward lower end histor rang potenti
drive growth via launch cosyntropin label altern acthar
start potenti licens extern asset add growth
driver neg includ declin nucynta end-market trend
could result partner collegium elect return right assertio
prospect opioid litig uncertainti even though larg
indemnifi assertio high leverag note assertio high leverag
lead wide bull/bear scenario risk reward
valuat final pt reduc previous base
ebitda previous ev/old ebitda
lower valuat multipl low end histor valuat
rang exhibit reflect nucynta long-term uncertainti nucynta see
exhibit rx declin note nucynta royalti repres
regard assertio opioid litig exposur indemnifi
nucynta prior lazanda prior market practic
limited/constrain recent year understand assertio liabl
nucynta lazanda litig liabil time assertio
own activ market drug acquisit
transfer collegium slan nucynta lazanda total
net sale assertio market nucynta lazanda
note assertio acquir right nucynta
manag emphas market practic conserv
compani transpar potenti addict risk per label
risk rate price target upsid risk includ neurolog cosyntropin
sale upsid nucynta end-market sale trend improv pursu
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
valu enhanc deal assertio indic interest transact add
elect return nucynta commerci right futur
disappoint key product trend cosyntropin approv delay neg
opioid litig develop lack strateg activ
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig talent
trial locat juri composit judg composit investor contact
legal advisor issu law relat subject matter
pt base ebitda close low end
histor rang pt base follow compon estimate
equiti valu divid share
bull case ebitda
bull case ebitda
result exceed expect transact enhanc prospect gralis
cambia sale beat project drive ebitda upsid cosyntropin
launch ramp consensu forecast transact add new growth
base case ebitda
base case ebitda
product declin moder due commerci initi assertio launch
cosyntropin new manag initi improv neurolog franchis
growth launch cosyntropin boost growth prospect
bear case ebitda
bear case ebitda
sale disappoint cosyntropin launch delay collegium termin nucynta
partnership manag turnaround effort disappoint ebitda
expect collegium indic intent termin nucynta
commerci agreement cosyntropin launch delayed/disappoint
multipl contract investor lose confid financi prospect
valuat balanc uncertain growth
in-lin portfolio declin moder
due new commerci effort
durat uncertain gener time
weak nucynta rx trend suggest risk
collegium termin nucynta agreement
futur
quarterli sale earn perform
nucynta trend collegium
product prescript price
opioid categori nucynta newsflow
quarterli financi result financi
risk achiev price
franchis rx trend sale above/below
trend higher/low expect
potenti termin nucynta agreement
exhibit monthli yoy sale trend incl nucynta franchis market
exhibit total compani ex-nucynta franchis weekli absolut trend yoy growth
exhibit nucynta immedi releas extend releas er declin yoy collegium
promot nucynta pay royalti assertio
exhibit nucynta nucynta er prescript mix note er prescript higher
valu collegium promot nucynta pay royalti assertio
nucynta pay royalti assertio
exhibit cambia absolut weekli absolut yoy
exhibit gralis absolut weekli absolut yoy
exhibit zipsor absolut weekli absolut yoy
exhibit incom statement margin valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
